baricitinib 4 MG Oral Tablet (EUA)
- RxCUI
- 2588561
- RxNorm name
- baricitinib 4 MG Oral Tablet (EUA)
- Display name
- baricitinib 4 MG Oral Tablet (EUA)
- Full name
- baricitinib 4 MG Oral Tablet (EUA)
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:07
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Olumiant | BARICITINIB | Eli Lilly and Company | 866e9f35-9035-4581-a4b1-75a621ab55cf | 2026-06-30 | Boxed warning, Warnings, Adverse reactions | 2588561 |
| Baricitinib | BARICITINIB | Eli Lilly and Company | 7052c055-fedf-453b-86bc-01f5465eb157 | 2022-05-10 | 2588561 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 866e9f35-9035-4581-a4b1-75a621ab55cf | baricitinib 4 MG Oral Tablet (EUA) [PSN] · baricitinib 4 MG Oral Tablet [SCD] · baricitinib 4 MG Oral Tablet (EUA) [SY] | 3 | 28 | These highlights do not include all the information needed to use OLUMIANT safely and effectively. See full prescribing information for OLUMIANT. OLUMIANT (baricitinib) tablets, for oral use Initial U.S. Approval: 2018 | 20260422 |
| 7052c055-fedf-453b-86bc-01f5465eb157 | baricitinib 4 MG Oral Tablet (EUA) [PSN] · baricitinib 4 MG Oral Tablet [SCD] · baricitinib 4 MG Oral Tablet (EUA) [SY] | 3 | 3 | BARICITINIB tablets, for oral use Emergency Use Authorization | 20220510 |